Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.

•Modified manufacturing process hepatitis B vaccine (mpHBV) studied in predialysis/dialysis patients.•4 Doses at 0, 1, 6, and 8 months: group 1 got mpHBV; group 2 got a licensed hepatitis B vaccine.•Population needed more vaccinations to reach seroprotective levels compared to healthy persons.•Reduced seroprotection rates support routine screening and re-dosing in this population.